European Parliament sends mixed signals to the bioplastics sector
more
Stories about Chemie
Takeda Pharma Vertrieb GmbH & Co. KG
The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
Zurich (ots/PRNewswire) - - TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six. - The therapeutical indication for TAKHZYRO® has been extended to patients aged 2 years and older.1 - Offers a New Preventative Treatment Option for young HAE patients with ...
moreBiomay Announces Expansion of GMP-Facilities to Offer mRNA Manufacturing and Aseptic Filling Services
moreTechnische Universität München
Start-up dedicated to developing new antibiotics
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Smartbax nominated for Falling Walls award Start-up dedicated to developing new antibiotics • New approach against resistant pathogens • Agent damages protein transport and energy balance of bacteria • Two TUM spin-offs nominated for Science Breakthrough of the Year at Falling Walls Summit It all began with basic research: While conducting laboratory experiments, a team ...
more- 4
Catalysing Change – Smart CO₂-Solutions Wanted for the “Best CO₂ Utilisation 2024” Innovation Award
One documentmore Gerresheimer at CPHI: focus on high-value solutions and sustainability
Duesseldorf (ots) - - Gerresheimer presents an extensive portfolio of containment solutions, drug delivery systems and digital therapy support - High-quality ready-to-fill solutions for biopharmaceuticals, cell and gene therapy - EcoDesign and environmentally friendly packaging options ensure greater sustainability Gerresheimer, an innovative system and solution ...
more
- 5
Be Part of the Chemistry and Materials Industry's Transition From Fossil to Renewable Carbon!
One documentmore GREIF-VELOX Maschinenfabrik GmbH
Sustainable Bagging of Carbon Black for the Electromobility Revolution
moreTakeda Pharma Vertrieb GmbH & Co. KG
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older
Zurich (ots/PRNewswire) - - If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. - Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile and Pharmacokinetics (PK) of Lanadelumab, in Combination with ...
more- 3
A Broad Range of Advanced Recycling Technologies Keeps Carbon in the Loop
2 Documentsmore FUCHS opens new, state-of-the-art plant in Ba Ria-Vung Tau, Vietnam
more- 4
Press Release - hubergroup presents new solvent-based, food-safe ink series for the Asian market
One documentmore
Hearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September
Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research meetings from August 29 to September 5. From August 29–31, Acousia ...
moreEnvironmental Impact Reduced: Madura Tea Switches All Flexible Packaging Materials to Paper from Koehler Paper in Conjunction with Gundlach Packaging Group
more- 2
Press release: STADA's excellent results in H1 2023 indicate a record annual profit of €1 bn, driven by Consumer Healthcare and Specialty
One documentmore - 3
CO₂-based Fuels and Chemicals Conference 2024 – Call for Abstracts and Posters
One documentmore LAMILUX Composites: Lightweights for dry freight trailers
One documentmoreGrünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
Aachen, Germany and Tokyo, Japan (ots) - - The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines - The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and ...
more
Koehler Paper Award Presented at Munich University of Applied Sciences (Hochschule München) for the Second Time
more- 5
Press Release - Innovative, sustainable, service-oriented: hubergroup Print Solutions with versatile flexo portfolio at Labelexpo Europe 2023
One documentmore LAMILUX Composites: Professional material for food transport
One documentmore- 4
Press Release - hubergroup to feature iray – its new UV flexo portfolio – at LMAI Conference 2023
One documentmore - 4
Shaping the sustainable fibre future with cellulose fibres – Abstract submissions open for the Cellulose Fibres Conference 2024
One documentmore - 5
No Sustainable Future Without Carbon Capture and Utilisation (CCU) – Why We Need Much More Political Recognition and Support for CCU
One documentmore
- 2
Press information: PreZero signs cooperation agreement on plastic circularity
One documentmore New Approach in Cancer Therapy With Innovative Mechanism-of-Action for Ferroptosis Induction
moreArtilysin® - A Groundbreaking "Green Pharma" Solution
more- 2
Press Release: Aurubis subsidiary RETORTE expanding selenium production for profitable growth markets
One documentmore - 4
Press Release - hubergroup Print Solutions with UV innovations at the IST UV Days 2023
One documentmore Croma-Pharma announces enrollment of first patient in hyaluronic acid dermal filler clinical trial in China
Vienna (ots/PRNewswire) - Croma-Pharma® ('Croma') announced today that in June the first patient will be enrolled in the clinical trial1 for the approval of its hyaluronic acid dermal filler Princess® Volume Plus Lidocaine2 in China. The randomised, multi-centre, evaluator blinded, parallel group, active ...
more
Previous12345678910Next